Yang Y - Search Results

1

Targeting autophagy plus high-dose CDK4/6 inhibitors in advanced HR+HER2- breast cancer: A phase 1b/2 trial.

Gong C, Lin Q, Qin T, Zeng Y, Xu F, Yang Y, Yin D, Duan Z, Chen CL, Wing-Cheong Chow L, Liu Q, Hamaï A, Mehrpour M, Lin Q, Li J, Song E. Gong C, et al. Among authors: yang y. Med. 2024 Dec 23:100559. doi: 10.1016/j.medj.2024.11.012. Online ahead of print. Med. 2024. PMID: 39731909

2

Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer.

Liu J, Wang Y, Tian Z, Lin Y, Li H, Zhu Z, Liu Q, Su S, Zeng Y, Jia W, Yang Y, Xu S, Yao H, Jiang W, Song E. Liu J, et al. Among authors: yang y. Nat Commun. 2022 May 31;13(1):3011. doi: 10.1038/s41467-022-30569-0. Nat Commun. 2022. PMID: 35641481 Free PMC article. Clinical Trial.

3

Association of FTH1-Expressing Circulating Tumor Cells With Efficacy of Neoadjuvant Chemotherapy for Patients With Breast Cancer: A Prospective Cohort Study.

Jia S, Yang Y, Zhu Y, Yang W, Ling L, Wei Y, Fang X, Lin Q, Hamaï A, Mehrpour M, Gao J, Tan W, Xia Y, Chen J, Jiang W, Gong C. Jia S, et al. Among authors: yang w, yang y. Oncologist. 2024 Jan 5;29(1):e25-e37. doi: 10.1093/oncolo/oyad195. Oncologist. 2024. PMID: 37390841 Free PMC article.

4

Patient-reported outcome and survival in premenopausal hormone receptor-positive breast cancer patients at moderate to high risk: comparing toremifene with aromatase inhibitor in a real-world study.

Yang Y, Gan F, Luo T, Lin Q, Yang W, Chen L, Zhang W, Liu Q, Gong C. Yang Y, et al. Among authors: yang w. MedComm (2020). 2024 Sep 15;5(10):e698. doi: 10.1002/mco2.698. eCollection 2024 Oct. MedComm (2020). 2024. PMID: 39286777 Free PMC article.

5

Preclinical study and phase 2 trial of neoadjuvant pyrotinib combined with chemotherapy in luminal/HER2-low breast cancer: PILHLE-001 study.

Gong C, Xia Y, Zhu Y, Yang Y, Lin Q, Liu Q, Yang W, Ling L, Zhong J, Duan Z, Zeng Y, Cheng Z, Shen J, Zeng Y, Chow LWC, Song E. Gong C, et al. Among authors: yang w, yang y. Cell Rep Med. 2024 Nov 19;5(11):101807. doi: 10.1016/j.xcrm.2024.101807. Epub 2024 Nov 6. Cell Rep Med. 2024. PMID: 39510070 Free PMC article. Clinical Trial.

6

Association between Homologous Recombination Repair Defect Status and Long-Term Prognosis of Early HER2-Low Breast Cancer: A Retrospective Cohort Study.

Chen J, Zhu Y, Wu W, Xu Y, Yang W, Ling L, Lin Q, Jia S, Xia Y, Liu Z, Yang Y, Gong C. Chen J, et al. Among authors: yang w, yang y. Oncologist. 2024 Jul 5;29(7):e864-e876. doi: 10.1093/oncolo/oyae021. Oncologist. 2024. PMID: 38366907 Free PMC article.

7

Sequential neoadjuvant chemotherapy using pegylated liposomal doxorubicin and cyclophosphamide followed by taxanes with complete trastuzumab and pertuzumab treatment for HER2-positive breast cancer: A phase II single-arm study.

Yang Y, Jin L, Li Y, Rao N, Gong C, Li S, Wu J, Zhao J, Ding L, Gan F, Zhang J, Feng R, Liu Z, Liu Q. Yang Y, et al. Chin J Cancer Res. 2024 Feb 29;36(1):55-65. doi: 10.21147/j.issn.1000-9604.2024.01.06. Chin J Cancer Res. 2024. PMID: 38455369 Free PMC article.

8

Circulating Tumor DNA Predicts the Response and Prognosis in Patients With Early Breast Cancer Receiving Neoadjuvant Chemotherapy.

Li S, Lai H, Liu J, Liu Y, Jin L, Li Y, Liu F, Gong Y, Guan Y, Yi X, Shi Q, Cai Z, Li Q, Li Y, Zhu M, Wang J, Yang Y, Wei W, Yin D, Song E, Liu Q. Li S, et al. Among authors: yang y. JCO Precis Oncol. 2020 Mar 27;4:PO.19.00292. doi: 10.1200/PO.19.00292. eCollection 2020. JCO Precis Oncol. 2020. PMID: 32923909 Free PMC article.

9

The Effect of Low and High Vacuum Drainage on the Postoperative Drainage of Breast Cancer: Insights from a Prospective, Non-Inferiority, Randomized Clinical Trial.

Lin W, Yang Y, Zhong W, Lin Q, Rao N, Liang G, Ling Y, Liu Z, Luo Q, Tian Z, Gong C. Lin W, et al. Among authors: yang y. Cancer Manag Res. 2020 Dec 3;12:12487-12496. doi: 10.2147/CMAR.S283031. eCollection 2020. Cancer Manag Res. 2020. PMID: 33299355 Free PMC article. Clinical Trial.

10

A 10-miRNA risk score-based prediction model for pathological complete response to neoadjuvant chemotherapy in hormone receptor-positive breast cancer.

Gong C, Cheng Z, Yang Y, Shen J, Zhu Y, Ling L, Lin W, Yu Z, Li Z, Tan W, Zheng C, Zheng W, Zhong J, Zhang X, Zeng Y, Liu Q, Huang RS, Komorowski AL, Yang ES, Bertucci F, Ricci F, Orlandi A, Franceschini G, Takabe K, Klimberg S, Ishii N, Toss A, Tan MP, Cherian MA, Song E. Gong C, et al. Among authors: yang es, yang y. Sci China Life Sci. 2022 Nov;65(11):2205-2217. doi: 10.1007/s11427-022-2104-3. Epub 2022 May 13. Sci China Life Sci. 2022. PMID: 35579777

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

110,716 results

Search Page

Filters